Administering Mounjaro: what the evidence says about technique, timing and getting it right

What the clinical evidence tells us about the injection method

The SURMOUNT-1 trial (2,539 adults, 72 weeks, published in the New England Journal of Medicine) established the weight-loss profile of tirzepatide at scale, but the protocol behind it also standardised how the drug was delivered. Subcutaneous injection, once weekly, into the abdomen, thigh or upper arm: that three-site system is now written into the licensed instructions and endorsed by the NHS tirzepatide medicines page. The reason those three sites are specified is pharmacokinetic — absorption rates are broadly similar across them, which means blood-level predictability is maintained whichever you use.

The KwikPen is a single-use, pre-filled device. There is no needle to attach, no dose to dial. You press the pen against the skin, press the button, and a short needle delivers the dose automatically. Most people describe the sensation as mild pressure rather than a sting, particularly as they settle into a weekly routine. Technique sharpens quickly. For a more detailed walkthrough of the physical steps, our guide on how to administer Mounjaro goes through each stage in sequence.

One practical note: injecting into skin that is red, bruised, scarred or affected by psoriasis is not recommended. The same applies to the navel area. Keep a mental note (or a simple written log) of which site you used each week.

Timing, storage and the routine that makes it easier

Mounjaro is taken on the same day each week; the time of day is your choice and can be adjusted if you need to move the day by a day or two. Consistency helps. Many people find anchoring the injection to something fixed (a Sunday morning before breakfast, or a weekday evening after the children are in bed) makes it easier to remember than setting a phone alert alone.

Before you inject, the pen should have been out of the fridge long enough to reach room temperature, which reduces injection-site discomfort. The exact time window the pen can safely sit at room temperature is stated in the leaflet inside the box; follow that document, not any figure quoted elsewhere, because the window is product-specific and can change between batches. Store unopened pens in the fridge at 2–8 °C. Never freeze them, and keep them away from direct light.

If you want to understand the broader clinical picture (how administering tirzepatide fits into a full treatment plan) the Mounjaro overview page covers the mechanism, licence and NHS versus private access in one place. For questions about the cost of treatment, our Mounjaro cost page sets out what a private prescription includes.

Site rotation and what to do if something looks wrong

Rotating between the abdomen, thigh and upper arm is not just a comfort measure. Repeated injections into the same small area can cause lipohypertrophy, a localised thickening of fatty tissue that impairs absorption. The result is less predictable drug delivery, not just a cosmetic concern. A simple rotation pattern, moving at least a couple of centimetres from the previous week's spot within the same body region, keeps the tissue healthy.

Minor redness or a small lump at the injection site is common and usually resolves within a day or two. Persistent swelling, pain that worsens rather than settles, or any sign of infection should be reported to your prescriber promptly. For less urgent questions about your technique or whether a reaction is within normal range, our support team is available seven days a week.

A short video demonstration can be worth more than paragraphs of text for a physical technique; our video guide to administering Mounjaro shows the full process in real time, which many patients find reassuring before their first injection. If you are wondering which specific body area tends to suit people best, this page on the best injection site goes into the evidence and practical trade-offs.

Safety considerations your prescriber will have discussed, and what to do if something concerns you

Administering tirzepatide is straightforward for most people, but a few safety points are worth knowing before you start. Gastrointestinal side effects (nausea, constipation, loose stools, indigestion) are the most commonly reported, and they tend to be at their most noticeable in the days following a dose increase rather than throughout treatment. They ease for most people within one to two weeks of each new strength.

More serious, though uncommon: severe stomach pain that does not settle and radiates toward the back may indicate pancreatitis, which requires urgent medical attention. The MHRA flagged this risk in a January 2026 Drug Safety Update covering GLP-1 medicines. If you experience this, stop the injection and seek help the same day. You can also report any suspected side effect through the MHRA Yellow Card scheme, which helps regulators monitor medicines after approval.

Pregnancy, breastfeeding and trying to conceive are all circumstances in which Mounjaro is not recommended. Oral contraceptives may be less reliably absorbed during the first four weeks of treatment and for four weeks after each dose increase; your prescriber will have covered this, but if you are unsure, ask. For context on one specific concern some patients raise, this page on Mounjaro and miscarriage risk addresses the available evidence carefully. If you have not yet started treatment and want clinical guidance on whether Mounjaro is right for you, speaking to our prescribers is the place to begin.